NASDAQ OMX

ILPA Issues Guidance for Limited Partners on Subscription Lines of Credit Used by Private Equity Funds

27.6.2017 13:00 | NASDAQ OMX

Del

Recommendations Center on Improved Disclosures by GPs

WASHINGTON and TORONTO, June 27, 2017 (GLOBE NEWSWIRE) -- The Institutional Limited Partners Association (ILPA) today released guidance regarding the use of subscription lines of credit facilities by private equity general partners (GPs).  In the document, ILPA outlines the risks and potential impact on limited partners (LPs) resulting from inadequate visibility into exposure to these credit lines. In response, the organization recommends that LPs seek greater disclosures from their fund managers around the use of subscription lines, as well as greater clarity in the partnership agreements around parameters for their use.

"Many limited partners understand how lines of credit can be beneficial to the cash flows of GPs and LPs alike, but over the last several years the practice has expanded significantly in size and scope," said Jennifer Choi, Managing Director of Industry Affairs, ILPA.  "ILPA wants to ensure that LPs have access to the necessary information regarding GPs' use of these facilities, and how they impact the alignment of interest between the two parties. Therefore, our recommendations are centered on a fundamental commitment to transparency and disclosure."

The ILPA guidance, which was developed in concert with LPs, GPs and industry advisers, includes the following recommendations:    

  • LPs should require their managers to disclose quarterly information on the size of the lines, number of days outstanding, specific uses of the capital, and impact of credit line facilities on reported IRRs.  During due diligence, LPs should request that prospective mangers provide the impact of subscription facilities on past reported performance.  
     
  • Within partnership agreements, waterfall provisions should specify that the date used to calculate the GPs' preferred return hurdle aligns to when the credit facility is drawn, rather than when capital is ultimately called from the LPs.
     
  • Partnership agreement provisions addressing use of subscription facilities should establish reasonable thresholds for their use, such as a maximum of 15-25% of all uncalled capital and no more than 180 days outstanding.  Such provisions should also make clear the burdens placed on the LPs whose commitments are used to secure the line.     

The full paper, "Subscription Lines of Credit and Alignment of Interests," can be found here. The ILPA intends to continuously reflect member feedback and new market conditions into this document and will publish, as needed, updates to this guidance on the ILPA website.

About the Institutional Limited Partners Association (ILPA)

The Institutional Limited Partners Association (ILPA) engages, empowers and connects limited partners to maximize their performance on an individual, institutional and collective basis. With more than 400 member institutions representing over US$1 trillion of invested capital, ILPA is the only global organization dedicated exclusively to advancing the interests of LPs and their beneficiaries through best-in-class education, research, advocacy and networking.  For more information, please visit ILPA.org.

Contact:
Emily Mendell
Head of Marketing and Communications, ILPA
emendell@ilpa.org
610-565-4692



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Institutional Limited Partners Association via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36Pressemelding

VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850  VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching

Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30Pressemelding

Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.  The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270.  A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company's website beginning approximately two hours after

Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22Pressemelding

Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year27.7.2017 13:00Pressemelding

Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period.   Financial and operating highlights during the first quarter of fiscal 2018 include: Fiscal first quarter worldwide revenue from Impella® heart pumps totaled $127.2 million, an increase of 30% compared to revenue of $97.8 million during the same period of the prior fiscal year.  U.S. revenue from Impella heart pumps grew 28% to $114.7 million and

TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00Pressemelding

-   Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia -   TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly

Concurrent Introduces Media Delivery Springboard26.7.2017 17:34Pressemelding

Fully Featured Entry Level Video-on-Demand and Live-Streaming Solutions for Cable Operators ATLANTA, July 26, 2017 (GLOBE NEWSWIRE) -- Concurrent (NASDAQ:CCUR), a global leader in storage, protection, transformation and delivery of visual assets, introduces today its new Media Delivery Springboard solutions, a cost-effective means for small and medium-sized independent cable operators to ingest, store, transform and deliver video-on-demand (VOD) and live-streaming content.   Traditional content delivery networks come with high start-up costs, which present a challenge for small and mid-size operators that may lack the necessary capital to invest in large-scale infrastructure. Concurrent's new Media Delivery Springboard helps independent cable operators with smaller budgets and limited resources remain competitive with an entry-level video delivery solution requiring minimal infrastructure investment.    There are three options available, including a VOD solution fo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom